China Grants Patent Protection to Microbix for its Influenza Vaccine Yield Enhancement Technology

Toronto-based Microbix Biosystems Inc. has been granted a patent by China’s State Intellectual Property Office for its Virusmax technology which enables egg-based vaccine manufacturers to increase the amount of influenza vaccine they produce each year. Virusmax already has patents in Canada, the US, India and Australia. Microbix specializes in developing proprietary biological technologies, including biotherapeutic drugs, vaccine technologies and animal reproduction technologies.